SPIB

Across TCGA pan-cancer cohorts, SPIB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPIB data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SPIB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPIB expression acts as an unfavorable survival marker.

LUAD, SARC, and LGG are the cancer types where SPIB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.338	0.834	.004	12	view →
SARC	OS	Median	All	0.144	0.745	.001	6	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
COAD	DFS	Median	All	0.118	0.556	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPIB–LUAD (OS)

Open the LUAD breakdown →